Jakob N Dupont

US Patent:

20070269831, Nov 22, 2007

Filed:

Sep 10, 2004

Appl. No.:

10/595135

Inventors:

David Spriggs - New York NY, US
Jakob Dupont - Pelham NY, US

Assignee:

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

International Classification:

G01N 33/574

US Classification:

435007100, 435007230

Abstract:

YKL-40 levels in serum and plasma samples provide as an indicator of both the presence of early stage ovarian cancer and of its aggressiveness. Thus testing for YKL-40 levels in patients at risk but not yet displaying symptoms associated with ovarian cancer, or in patients newly diagnosed with early stage ovarian cancer (Stage I or II) enhance both the detection of early stage ovarian cancer and selection of treatment protocols used for early stage ovarian cancer patients.

US Patent:

20110206662, Aug 25, 2011

Filed:

Feb 22, 2011

Appl. No.:

13/032532

Inventors:

Jakob Dupont - Hillsborough CA, US
Cornelia Irl - Basel, CH

Assignee:

GENENTECH, INC. - South San Francisco CA

International Classification:

A61K 39/395
A61P 35/00
G09B 19/00
G06Q 50/00

US Classification:

4241331, 4241581, 434262, 705500

Abstract:

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

US Patent:

20130323266, Dec 5, 2013

Filed:

May 16, 2013

Appl. No.:

13/895543

Inventors:

John A. Lewicki - Los Gatos CA, US
Wan-Ching Yen - Foster City CA, US
Jakob Dupont - Hillsborough CA, US

Assignee:

OncoMed Pharmaceuticals, Inc. - Redwood City CA

International Classification:

A61K 39/395
A61K 45/06

US Classification:

4241721

Abstract:

The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a Notch2/3 antibody.

US Patent:

20050281822, Dec 22, 2005

Filed:

Jun 17, 2005

Appl. No.:

11/155269

Inventors:

Jesse Cedarbaum - Larchmont NY, US
Christopher Azzoli - New York NY, US
Mark Kris - New York NY, US
Jakob Dupont - Pelham NY, US

International Classification:

A61K039/395
A61K038/18

US Classification:

424145100, 514002000

Abstract:

Methods for treating a human patient suffering from malignant pleural effusion by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF trap protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.

US Patent:

20210403553, Dec 30, 2021

Filed:

May 26, 2021

Appl. No.:

17/330716

Inventors:

- Redwood City CA, US
Timothy Charles Hoey - San Francisco CA, US
Austin L. Gurney - San Francisco CA, US
Julie Michelle Roda - Foster City CA, US
Minu K. Srivastava - Sunnyvale CA, US
Inkyung Park - Palo Alto CA, US
Jakob Dupont - Hillsborough CA, US

International Classification:

C07K 16/28
A61K 39/395
C12N 15/113
A61K 31/282
A61K 31/519

Abstract:

The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.

US Patent:

20180273618, Sep 27, 2018

Filed:

Feb 6, 2018

Appl. No.:

15/889532

Inventors:

- Redwood City CA, US
Timothy Charles HOEY - Hillsborough CA, US
Austin L. GURNEY - San Francisco CA, US
Julie Michelle RODA - Foster City CA, US
Minu K. SRIVASTAVA - Sunnyvale CA, US
Inkyung PARK - Palo Alto CA, US
Jakob DUPONT - Hillsborough CA, US

International Classification:

C07K 16/28
A61K 31/519
A61K 39/395
A61K 31/282
A61K 39/00

Abstract:

The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.

US Patent:

20170299598, Oct 19, 2017

Filed:

Feb 1, 2017

Appl. No.:

15/421635

Inventors:

- Redwood City CA, US
Robert Joseph Stagg - Moraga CA, US
Jakob Dupont - Hillsborough CA, US

International Classification:

G01N 33/574
A61K 31/403
A61K 31/4045
A61K 31/519
G01N 33/74
C07K 16/30
A61K 31/282
A61K 39/395
A61K 31/7068
A61K 31/706
A61K 45/06
G01N 33/68
A61K 39/00

Abstract:

Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.

US Patent:

20170157245, Jun 8, 2017

Filed:

Apr 3, 2015

Appl. No.:

15/301138

Inventors:

- Redwood City CA, US
Jakob DUPONT - Hillsborough CA, US

International Classification:

A61K 39/00

Abstract:

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly gastric cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit growth of a gastric tumor. Also described are methods of treating gastric cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a gastric tumor or gastric cancer.